Liminatus Pharma, Inc Press Releases

• Published on August 18, 2025 - 15:59 GMT

  

  Exploring the Potential of IBA101 in Combination with PD-1/PD-L1 Blockade

  Patent Expiry and the Need for New Therapeutic Strategies Liminatus Pharma, Inc (NASDAQ:LIMN) LA PALMA, CA, UNITED STATES, August 18, 2025 /⁨EINPresswire.com⁩/ -- PD-1/PD-L1 inhibitors such as Keytruda, Opdivo, Tecentriq, Imfinzi, and Libtayo have been …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on August 18, 2025 - 13:00 GMT

  Liminatus Pharma Highlights Life-Saving Potential of Next-Generation Pancreatic Cancer Screening Test

  Collaboration with Samda Biolab and INNOCS AI Targets Early Detection for Thousands of Patients Worldwide LA PALMA, CA, UNITED STATES, August 18, 2025 /⁨EINPresswire.com⁩/ -- Liminatus Pharma, Inc. (Nasdaq: LIMN) today reaffirmed the promising clinical …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on July 7, 2025 - 13:14 GMT

  

  Liminatus Pharma Announces New Clinical Milestone in Pancreatic Cancer Screening with Samda Biolab and INNOCS AI

  Liminatus Pharma, Inc (NASDAQ:LIMN) LA PALMA, CA, UNITED STATES, July 7, 2025 /⁨EINPresswire.com⁩/ -- Liminatus Pharma (Nasdaq: LIMN) has announced promising new clinical results that could significantly advance early detection of pancreatic cancer. This …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on July 2, 2025 - 21:00 GMT

  Liminatus Pharma Forms Strategic Consortium with Samda and INNOCS AI to Advance Next-Gen Pancreatic Cancer Diagnostics

  Liminatus Pharma, Inc (NASDAQ:LIMN) FULLERTON, CA, UNITED STATES, July 2, 2025 /⁨EINPresswire.com⁩/ -- Liminatus Pharma today announced that it has entered into a Memorandum of Understanding (MOU) to form a research and development consortium with Samda …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on June 26, 2025 - 22:18 GMT

  Liminatus Pharma (LIMN) Advances CD47 Immunotherapy with Enhanced Safety Profile and Korean Clinical Collaboration

  Liminatus Pharma, Inc (NASDAQ:LIMN) LA PALMA, CA, UNITED STATES, June 26, 2025 /⁨EINPresswire.com⁩/ -- Liminatus is advancing a second-generation CD47 antibody, IBA101, intended to improve the safety and performance profile of macrophage-based …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on June 24, 2025 - 17:02 GMT

  Liminatus Pharma Charts Dual-Front Attack on Cancer with IBA101

  Liminatus Pharma, Inc (NASDAQ:LIMN) LA PALMA, CA, UNITED STATES, June 24, 2025 /⁨EINPresswire.com⁩/ -- Next-generation CD47 inhibitor advances toward human trials in U.S. and Korea, with the prospect of safer, more potent immunotherapy Since its Nasdaq …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...